Pfizer’s Vyndamax will be free from generics competition until 2031 in a boost to the company’s revenue streams.

Pfizer inking the last of three settlements to postpone copycats to its transthyretin amyloid cardiomyopathy (ATTR-CM) med ...

As Pfizer gears up to defend its patents on transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis in court this week, ...

Pfizer has reached agreements with Dexcel Pharma, Hikma Pharmaceuticals and Cipla, regarding lawsuits filed in the U.S.

Settlements delaying the arrival of generic versions of tafamidis will protect billions in Pfizer revenue and have ...

Pfizer has reached settlements with three generic drugmakers, pushing back U.S. market entry of Vyndamax copies until mid-2031, pending other litigation. The move preserves billions in annual revenue ...

Vyndamax, which treats heart problems in adults with cardiomyopathy, along with its related drugs, generated $6.3 billion in ...

The settlements delay the entry of generic copies of Pfizer’s Vyndamax by almost three years, stabilizing sales of a drug ...

April 28 (Reuters) - Pfizer said on Tuesday it has settled patent disputes with three generic drugmakers over its blockbuster ...

Pfizer Inc.'s agreements dropping two generic-drug makers from a patent case over copies of its blockbuster heart drug Vyndamax left Hikma Pharmaceuticals Plc the last remaining defendant for a bench ...

Pfizer has reached settlements with three drugmakers to delay US generic competition for its $6.4 billion heart drug Vyndamax until 2031, extending revenue stability amid looming industry pressures.